Trials / Completed
CompletedNCT06052748
A Study to Evaluate the Efficacy and Safety of AD-223
A Multicenter, Randomized, Double-blind, Active-control, Phase III Study to Evaluate the Efficacy and Safety of AD-223A and AD-223B Combination Therapy in Patients With Essential Hypertension
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 502 (actual)
- Sponsor
- Addpharma Inc. · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of AD-223
Detailed description
Condition or disease : hypertension
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AD-223A | PO, Once daily(QD), 8weeks |
| DRUG | AD-223B | PO, Once daily(QD), 8weeks |
| DRUG | AD-223C | PO, Once daily(QD), 8weeks |
| DRUG | AD-223A Placebo | PO, Once daily(QD), 8weeks |
| DRUG | AD-223B Placebo | PO, Once daily(QD), 8weeks |
| DRUG | AD-223C Placebo | PO, Once daily(QD), 8weeks |
Timeline
- Start date
- 2024-02-15
- Primary completion
- 2025-03-27
- Completion
- 2025-04-02
- First posted
- 2023-09-25
- Last updated
- 2025-04-04
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT06052748. Inclusion in this directory is not an endorsement.